|
Market Closed -
Other stock markets
|
After hours 05:30:01 pm | |||
| 470.72 USD | -1.34% |
|
480.10 | +1.99% |
| 05:01pm | Vertex Pharmaceuticals Bumps Up Fiscal Year Outlook on Growth of Cystic Fibrosis Drugs | DJ |
| 04:10pm | Vertex Pharmaceuticals Q2 Adjusted Earnings, Revenue Rise; Lifts 2026 Guidance | MT |
Company Valuation: Vertex Pharmaceuticals Incorporated
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55,834 | 74,127 | 104,849 | 103,707 | 115,026 | 121,091 | - | - |
| Change | - | 32.76% | 41.44% | -1.09% | 10.91% | 5.27% | - | - |
| Enterprise Value (EV) 1 | 48,309 | 63,349 | 93,630 | 97,591 | 108,418 | 107,346 | 102,474 | 97,434 |
| Change | - | 31.13% | 47.8% | 4.23% | 11.09% | -0.99% | -4.54% | -4.92% |
| P/E | 24.4x | 22.5x | 29.3x | -194x | 29.6x | 27.3x | 24x | 19.6x |
| PBR | 5.53x | 5.33x | 5.96x | 6.4x | 6.17x | 5.46x | 4.53x | 3.81x |
| PEG | - | 0.5x | 3.51x | 2x | -0x | 1.9x | 1.8x | 0.9x |
| Capitalization / Revenue | 7.37x | 8.3x | 10.6x | 9.41x | 9.58x | 9.28x | 8.43x | 7.48x |
| EV / Revenue | 6.38x | 7.09x | 9.49x | 8.86x | 9.03x | 8.22x | 7.14x | 6.02x |
| EV / EBITDA | 10.8x | 12.8x | 20.6x | 108x | 19.8x | 18.5x | 15.4x | 12.7x |
| EV / EBIT | 11.1x | 13.2x | 21.4x | 140x | 20.6x | 19.4x | 16.1x | 12.9x |
| EV / FCF | 20.1x | 16.1x | 28.1x | -123x | 33.9x | 21.9x | 20.2x | 16.5x |
| FCF Yield | 4.99% | 6.2% | 3.56% | -0.81% | 2.95% | 4.56% | 4.96% | 6.07% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 9.01 | 12.82 | 13.89 | -2.08 | 15.32 | 17.5 | 19.85 | 24.34 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 7,574 | 8,931 | 9,869 | 11,020 | 12,001 | 13,052 | 14,358 | 16,193 |
| EBITDA 1 | 4,470 | 4,941 | 4,556 | 902.8 | 5,473 | 5,793 | 6,652 | 7,659 |
| EBIT 1 | 4,344 | 4,793 | 4,375 | 695.6 | 5,263 | 5,534 | 6,348 | 7,542 |
| Net income 1 | 2,342 | 3,322 | 3,620 | -535.6 | 3,953 | 4,508 | 5,124 | 6,248 |
| Net Debt 1 | -7,525 | -10,778 | -11,218 | -6,116 | -6,608 | -13,745 | -18,617 | -23,657 |
| Reference price 2 | 219.60 | 288.78 | 406.89 | 402.70 | 453.36 | 477.10 | 477.10 | 477.10 |
| Nbr of stocks (in thousands) | 254,252 | 256,691 | 257,683 | 257,529 | 253,719 | 253,805 | - | - |
| Announcement Date | 1/26/22 | 2/7/23 | 2/5/24 | 2/10/25 | 2/12/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 27.26x | 8.22x | 18.53x | -.--% | 121B | |
| 35.03x | 12.19x | 25.61x | 0.59% | 1,024B | |
| 27.48x | 6.29x | 17.54x | 2.1% | 618B | |
| 32.57x | 7.42x | 15.36x | 2.76% | 443B | |
| 19.7x | 4.68x | 11.59x | 2.83% | 349B | |
| 22.21x | 5.74x | 14.32x | 2.8% | 297B | |
| 21.76x | 4.48x | 12.7x | 1.96% | 264B | |
| 13.48x | 5.05x | 10.4x | 3.71% | 209B | |
| 25.29x | 6.61x | 11.66x | 2.62% | 208B | |
| -46.92x | 5.63x | 31.08x | 2.53% | 162B | |
| Average | 17.79x | 6.63x | 16.88x | 2.19% | 369.48B | |
| Weighted average by Cap. | 24.44x | 7.72x | 18.24x | 1.94% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- VRTX Stock
- Valuation Vertex Pharmaceuticals Incorporated
Select your edition
All financial news and data tailored to specific country editions
